Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 366
- Registration Number
- NCT04471428
- Locations
- 🇺🇸
Kaiser Permanente - San Diego, San Diego, California, United States
🇦🇹LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz, Austria
🇦🇹Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt., Salzburg, Austria
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
- Conditions
- Interventions
- First Posted Date
- 2020-06-18
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 221
- Registration Number
- NCT04436744
- Locations
- 🇺🇸
UCLA - Burbank, Burbank, California, United States
🇺🇸UCLA Hematology/Oncology-San Luis Obispo, San Luis Obispo, California, United States
🇺🇸Orlando Health Inc., Orlando, Florida, United States
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1479
- Registration Number
- NCT04432831
- Locations
- 🇺🇸
Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸Retinal Research Institute, LLC, Phoenix, Arizona, United States
🇺🇸Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States
A Phase III Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors.
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 204
- Registration Number
- NCT04434092
- Locations
- 🇵🇱
MTZ Clinical Research Powered by Pratia, Warszawa, Poland
🇲🇽Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico
🇵🇹Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E., Lisbon, Portugal
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 55
- Registration Number
- NCT04431726
- Locations
- 🇦🇺
Perth Children's Hospital, Nedlands, Western Australia, Australia
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 190
- Registration Number
- NCT04432584
- Locations
- 🇫🇷
Institut Paoli Calmette; Service d'Hématologie Clinique, Marseille, France
🇬🇷General Hospital of Athens LAIKO, Athens, Greece
🇬🇷Attikon University General Hospital, Chaidari, Greece
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT04426825
- Locations
- 🇨🇳
Sun Yet-sen University Cancer Center, Guangzhou City, China
🇨🇳Beijing Hospital; Internal Medicine-Oncology, Beijing, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, China
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 74
- Registration Number
- NCT04428281
- Locations
- 🇺🇸
UCLA Neuropsychiatric Institute, Los Angeles, California, United States
🇺🇸Rush Medical Center, Chicago, Illinois, United States
🇺🇸Mayo Clinic - Rochester, Rochester, Minnesota, United States
A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT04422210
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
🇺🇸Emory University, Atlanta, Georgia, United States
🇩🇰Rigshospitalet; Onkologisk Klinik, København Ø, Denmark
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2022-02-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 649
- Registration Number
- NCT04409262
- Locations
- 🇪🇸
Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
🇺🇸Baylor Scott & White Medical Center - Irving, Irving, Texas, United States
🇧🇷Hospital Nossa Senhora das Graças; Setor de Pesquisa em Neurologia, Curitiba, PR, Brazil